NCT06784648 - Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

June 30, 2031

Conditions

Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K MutatedMelanoma RecurrentMelanoma Stage III or IVMelanomaMelanoma Negative for bRAFMelanoma Negative for nRASMelanomasUveal Melanoma, Metastatic

Interventions

BIOLOGICAL

pembrolizumab (KEYTRUDA®)

fixed dose 200mg

BIOLOGICAL

BI-1607

Each cohorts will receive either 350mg or 700mg per cycle for 4 cycles

BIOLOGICAL

Ipilimumab (YervoyTM, 50 mg/10 mL solution)

Each cohort will receive either 1mg/kg or 3mg/kg for 4 cycles

Trial Locations (9)

Unknown

RECRUITING

Charité - Universitatsmedizin Berlin, Berlin

RECRUITING

University Hospital Essen, Essen

RECRUITING

University Hospital Heidelberg, Heidelberg

RECRUITING

University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ), Mannheim

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

RECRUITING

University Hospital 12 de Octubre, Madrid

W1G 6AD

RECRUITING

Sarah Cannon Research Institute UK, London

CF14 2TL

RECRUITING

Velindre Cancer Centre, Cardiff

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester